<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261803</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0861</org_study_id>
    <secondary_id>2019-A03076-51</secondary_id>
    <nct_id>NCT04261803</nct_id>
  </id_info>
  <brief_title>FH Detection in Children by Salivary Test</brief_title>
  <acronym>DEPEDIACOL</acronym>
  <official_title>Familial Hypercholesterolemia Non Invasive Detection in Children by Salivary Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial Hypercholesterolemia is a common cause of premature coronary heart disease, it is&#xD;
      present in 1 per 500 to 1 per 250 people of the general population. Studies on families of&#xD;
      Hypercholesterolemia have shown that children with Hypercholesterolemia have a major increase&#xD;
      in risk of coronary heart disease after the age of 20. The difference between&#xD;
      Hypercholesterolemia and normal children in their atherogenic profil begin at the age of&#xD;
      Nowadays , systematic screening techniques are not well implemented whereas their are clear&#xD;
      World health organization guidelines.&#xD;
&#xD;
      International studies show treatment must be initiated early as at the age of eight years&#xD;
      old.&#xD;
&#xD;
      In pediatry, Parents can be reluctant to practice blood test on their children. In order to&#xD;
      allow more patients to be diagnosed and treated early enough to prevent major complications&#xD;
      we need to find an non invasive test.&#xD;
&#xD;
      The main objective is to define the level of detection of cholesterol in saliva with two&#xD;
      enzymatic tests. Furthermore we aim to evaluate the performance of salivary detection of&#xD;
      cholesterol in children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Actual">August 26, 2020</completion_date>
  <primary_completion_date type="Actual">August 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>salivary cholesterol concentration</measure>
    <time_frame>Day 1</time_frame>
    <description>the sample will be obtained during one visit non dedicated to this study (following-visit in nutrition for hypercholesterolemia children and before surgery for control children), the swabs of all the 60 patients will be used in two different methods of enzymatic tests.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Hyperlipoproteinemia Type II</condition>
  <arm_group>
    <arm_group_label>Familial Hypercholesterolemia children</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control children</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>salivary sample</intervention_name>
    <description>spit of saliva in a tube</description>
    <arm_group_label>Control children</arm_group_label>
    <arm_group_label>Familial Hypercholesterolemia children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>2millilitter blood test</description>
    <arm_group_label>Control children</arm_group_label>
    <arm_group_label>Familial Hypercholesterolemia children</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      saliva and blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Familial Hypercholesterolemia children group Control children group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  children under 18 years old, with familial hypercholesterolemia&#xD;
&#xD;
          -  children under 18 years old, intending surgery&#xD;
&#xD;
          -  being able to spit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  poor dental health&#xD;
&#xD;
          -  for control patients: to have a known cholesterol disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel PERETTI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon gastro-enterological hepatology and nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon gastro-enterological hepatology and nutrition</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>familial hypercholesterolemia</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

